13F filer · CIK 1766721
Aisling Capital Management LP
NEW YORK, NY · filing since Q4 2018 · last filing Aug 13, 2026
Reported value
$471.6M
$-4.7M vs prior
Positions
14
New / sold out
1 / 0
Added / reduced
0 / 1
Turnover
0.4%
buys $1.9M · sells $37.2M
Top-10 weight
99.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | VTV THERAPEUTICS INC | +50,000 | – | +$1.9M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | BRIDGEBIO PHARMA INC | -500,000 | -9.8% | $-37.2M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | BRIDGEBIO PHARMA INCCOM | 4,589,611 | $341.8M | 72.48% |
| 2 | MONTE ROSA THERAPEUTICS INCCOM | 1,555,664 | $37.6M | 7.98% |
| 3 | SYNDAX PHARMACEUTICALS INCCOM | 1,316,806 | $28.8M | 6.10% |
| 4 | COMPASS PATHWAYS PLCSPONSORED ADS | 1,432,336 | $20.3M | 4.30% |
| 5 | BICARA THERAPEUTICS INCCOM | 568,919 | $16.9M | 3.58% |
| 6 | BRIDGEBIO ONCOLOGY THERAPEUTCOM NEW | 1,018,018 | $7.8M | 1.64% |
| 7 | SCHOLAR ROCK HLDG CORPCOM | 77,031 | $4.2M | 0.90% |
| 8 | UROGEN PHARMA LTDCOM | 108,000 | $4.0M | 0.84% |
| 9 | BIOMEA FUSION INCCOM | 2,048,757 | $3.0M | 0.64% |
| 10 | ACLARIS THERAPEUTICS INCCOM | 434,455 | $2.3M | 0.49% |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.